PL1874765T3 - Pochodne mocznika, sposoby ich otrzymywania i zastosowanie - Google Patents

Pochodne mocznika, sposoby ich otrzymywania i zastosowanie

Info

Publication number
PL1874765T3
PL1874765T3 PL06724709T PL06724709T PL1874765T3 PL 1874765 T3 PL1874765 T3 PL 1874765T3 PL 06724709 T PL06724709 T PL 06724709T PL 06724709 T PL06724709 T PL 06724709T PL 1874765 T3 PL1874765 T3 PL 1874765T3
Authority
PL
Poland
Prior art keywords
manufacture
methods
urea derivatives
urea
derivatives
Prior art date
Application number
PL06724709T
Other languages
English (en)
Inventor
Pierre Deprez
Helène JARY
Taoues Temal
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Publication of PL1874765T3 publication Critical patent/PL1874765T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Treating Waste Gases (AREA)
PL06724709T 2005-04-29 2006-04-24 Pochodne mocznika, sposoby ich otrzymywania i zastosowanie PL1874765T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0504360A FR2885129B1 (fr) 2005-04-29 2005-04-29 Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP06724709A EP1874765B1 (en) 2005-04-29 2006-04-24 Urea derivatives, methods for their manufacture and uses thereof
PCT/EP2006/004166 WO2006117211A2 (en) 2005-04-29 2006-04-24 Urea derivatives methods for their manufacture and uses thereof

Publications (1)

Publication Number Publication Date
PL1874765T3 true PL1874765T3 (pl) 2012-08-31

Family

ID=35311522

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06724709T PL1874765T3 (pl) 2005-04-29 2006-04-24 Pochodne mocznika, sposoby ich otrzymywania i zastosowanie

Country Status (25)

Country Link
US (2) US8247412B2 (pl)
EP (2) EP1874765B1 (pl)
JP (1) JP4995189B2 (pl)
KR (1) KR20080003380A (pl)
CN (1) CN101238120A (pl)
AR (1) AR056991A1 (pl)
AT (1) ATE548368T1 (pl)
AU (1) AU2006243328B2 (pl)
BR (1) BRPI0611025A2 (pl)
CA (1) CA2605008A1 (pl)
CR (1) CR9469A (pl)
CY (1) CY1112960T1 (pl)
DK (1) DK1874765T3 (pl)
EA (1) EA200702375A1 (pl)
ES (1) ES2384052T3 (pl)
FR (1) FR2885129B1 (pl)
HR (1) HRP20120424T1 (pl)
IL (1) IL186854A0 (pl)
NO (1) NO20076145L (pl)
PL (1) PL1874765T3 (pl)
PT (1) PT1874765E (pl)
TW (1) TW200714598A (pl)
UY (1) UY29510A1 (pl)
WO (1) WO2006117211A2 (pl)
ZA (1) ZA200708871B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
ATE450262T1 (de) 2005-11-25 2009-12-15 Galapagos Sas Harnstoff-derivate als calcium-rezeptor- modulatoren
WO2007124465A2 (en) * 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2008121386A2 (en) 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
EP2156846B1 (en) * 2007-05-08 2014-08-13 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diarrhea
AU2008275595B2 (en) * 2007-07-10 2013-11-14 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016951B1 (en) 2013-07-02 2017-05-31 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31574A0 (en) 1968-02-13 1969-04-30 Ciba Ltd Use of certain ureas for combating weeds
US3897242A (en) * 1968-02-13 1975-07-29 Ciba Geigy Ag Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) * 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4521583A (en) * 1984-02-09 1985-06-04 American Cyanamid Company Curable epoxy resin compositions
US4594373A (en) * 1984-02-09 1986-06-10 American Cyanamid Company Curable epoxy resin compositions
FR2601363B1 (fr) * 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
US5227397A (en) * 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
CA2062810A1 (en) 1989-07-03 1991-01-04 Bruce D. Cherksey Use of polyamines as ionic-channel regulating agents
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
CA2096528C (en) 1990-11-19 2005-12-06 Kathryn Lea Reed Retroviral protease inhibitors
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0641333B1 (en) 1992-05-20 1996-08-14 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
KR100360964B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성 프로테아제 억제 화합물의 중간체의제조방법
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
DE69515465T2 (de) * 1994-11-04 2000-08-03 Santen Pharmaceutical Co Ltd Neue hydroxy-substituierte 1,3-dialkyl-harnstoffderivate
EP0798291B1 (en) 1994-12-14 2002-09-11 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
JP3306571B2 (ja) 1995-06-28 2002-07-24 参天製薬株式会社 エンドセリン変換酵素阻害剤
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
SG99290A1 (en) * 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
EP1019367A1 (en) 1997-08-05 2000-07-19 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
JP2001501979A (ja) 1998-01-21 2001-02-13 ザイモジェネティクス，インコーポレイティド カルシトニン擬態物としてのジアルキルウレア
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) * 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
FR2820136A1 (fr) * 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6598746B2 (en) * 2001-09-13 2003-07-29 Washburn Graphics, Inc. Display carton having an internally reinforced hanger panel
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
JP2005336173A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 骨粗鬆症治療剤
HUE028373T2 (en) 2004-05-28 2017-02-28 Mitsubishi Tanabe Pharma Corp Arylalkylamines and processes for their preparation
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US7585886B2 (en) * 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
ATE450262T1 (de) * 2005-11-25 2009-12-15 Galapagos Sas Harnstoff-derivate als calcium-rezeptor- modulatoren
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
AU2008275595B2 (en) 2007-07-10 2013-11-14 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Also Published As

Publication number Publication date
CN101238120A (zh) 2008-08-06
EP1874765A2 (en) 2008-01-09
JP4995189B2 (ja) 2012-08-08
EA200702375A1 (ru) 2008-06-30
IL186854A0 (en) 2008-02-09
ZA200708871B (en) 2009-03-25
EP1874765B1 (en) 2012-03-07
US8247412B2 (en) 2012-08-21
WO2006117211A3 (en) 2007-01-11
DK1874765T3 (da) 2012-06-18
TW200714598A (en) 2007-04-16
KR20080003380A (ko) 2008-01-07
BRPI0611025A2 (pt) 2016-11-16
AU2006243328A1 (en) 2006-11-09
WO2006117211A2 (en) 2006-11-09
NO20076145L (no) 2008-01-28
PT1874765E (pt) 2012-05-25
CA2605008A1 (en) 2006-11-09
US20100240889A1 (en) 2010-09-23
US20120283255A1 (en) 2012-11-08
FR2885129B1 (fr) 2007-06-15
ATE548368T1 (de) 2012-03-15
ES2384052T3 (es) 2012-06-28
AU2006243328B2 (en) 2011-09-08
AR056991A1 (es) 2007-11-07
HRP20120424T1 (hr) 2012-06-30
FR2885129A1 (fr) 2006-11-03
EP2354137A1 (en) 2011-08-10
CY1112960T1 (el) 2016-04-13
UY29510A1 (es) 2006-12-29
JP2008539186A (ja) 2008-11-13
CR9469A (es) 2008-03-06

Similar Documents

Publication Publication Date Title
PL1874765T3 (pl) Pochodne mocznika, sposoby ich otrzymywania i zastosowanie
IL196527A (en) The history of the terroir is preserved, their processes and their use
EP1937766A4 (en) MODIFIED POLYAMIDES, USES THEREOF AND MANUFACTURING METHOD THEREFOR
EP1925617A4 (en) Heterocyclic compound, method of preparation and use
EP1764360A4 (en) UREA DERIVATIVE
EP2223921B8 (en) 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents
EP1990337A4 (en) CHINAZOLINE DERIVATIVES, METHOD OF MANUFACTURE AND USES THEREOF
PL1954745T3 (pl) Preparat środka zwiększającego przyczepność, sposób jego wytwarzania oraz jego zastosowanie
HUP0500920A2 (en) Oxadiazole derivatives, process for their preparation and their use
GB0613674D0 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
EP1961753A4 (en) DERIVATIVES OF PIRAZOLOPYRIMIDINONE, THEIR PREPARATION AND USE
IL193155A0 (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP1875812A4 (en) RAPIDLY SOLUBLE GRANULE AND METHOD OF PRODUCTION OF SAID GRANULE
GB0516245D0 (en) Process, composition and compound
GB2440089B8 (en) Regeneration system, its production and use
IL190334A0 (en) Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
HK1100946A1 (en) 1-a-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
IL188185A0 (en) Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
ZA200709285B (en) Method for the production of pigs, and pigs
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
ZA200805284B (en) Tetrafluorotoluene compound, method for producing same and use thereof
ZA200805167B (en) Diphenyl urea derivatives